1. AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion
   Daniel R. Matson et al, 2017, Experimental and Molecular Pathology CrossRef
2. Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies
   Sigurdis Haraldsdottir et al, 2018, JCO Precision Oncology CrossRef
3. Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
   Xiaoni Gao et al, 2023, Frontiers in Oncology CrossRef
4. Biological functions and research progress of eIF4E
   Xiaocong Chen et al, 2023, Frontiers in Oncology CrossRef
5. Evaluation of drug efficacy based on the spatial position comparison of drug–target interaction centers
   Yu Ding et al, 2020, Briefings in Bioinformatics CrossRef
6. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment
   Livia Manzella et al, 2019, International Journal of Molecular Sciences CrossRef
7. Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
   Maria R. Cavallo et al, 2024, Cell Death Discovery CrossRef
8. Therapeutic advances in anaplastic thyroid cancer: a current perspective
   Shikha Saini et al, 2018, Molecular Cancer CrossRef
9. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
   Tanner Fullmer et al, 2021, Frontiers in Endocrinology CrossRef
10. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
    Vivek Subbiah et al, 2017, Clinical Cancer Research CrossRef
11. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
    Razelle Kurzrock et al, 2019, Clinical Cancer Research CrossRef
12. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
    Rachna T Shroff et al, 2017, British Journal of Cancer CrossRef
13. Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma
    Cinzia Lanzi et al, 2019, Cancers CrossRef
14. Targeted therapy and drug resistance in thyroid cancer
    Yujie Zhang et al, 2022, European Journal of Medicinal Chemistry CrossRef
15. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells
    Nobuhiko Yokoyama et al, 2017, Scientific Reports CrossRef
16. Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer
    Daniela Gentile et al, 2020, Medical Oncology CrossRef